EMBC vs. ATRI, SILK, KIDS, AORT, FNA, ATRC, SIBN, OFIX, IRMD, and MDXG
Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Atrion (ATRI), Silk Road Medical (SILK), OrthoPediatrics (KIDS), Artivion (AORT), Paragon 28 (FNA), AtriCure (ATRC), SI-BONE (SIBN), Orthofix Medical (OFIX), Iradimed (IRMD), and MiMedx Group (MDXG). These companies are all part of the "surgical & medical instruments" industry.
Atrion (NASDAQ:ATRI) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability.
Embecta has higher revenue and earnings than Atrion. Embecta is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Embecta had 8 more articles in the media than Atrion. MarketBeat recorded 19 mentions for Embecta and 11 mentions for Atrion. Embecta's average media sentiment score of 0.77 beat Atrion's score of 0.43 indicating that Atrion is being referred to more favorably in the media.
66.2% of Atrion shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 22.8% of Atrion shares are owned by company insiders. Comparatively, 0.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Embecta has a consensus price target of $13.00, suggesting a potential downside of 10.96%. Given Atrion's higher probable upside, analysts clearly believe Embecta is more favorable than Atrion.
Atrion received 129 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 55.36% of users gave Atrion an outperform vote while only 0.00% of users gave Embecta an outperform vote.
Atrion pays an annual dividend of $8.80 per share and has a dividend yield of 1.8%. Embecta pays an annual dividend of $0.60 per share and has a dividend yield of 4.1%. Atrion pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Embecta pays out 49.6% of its earnings in the form of a dividend. Atrion has increased its dividend for 21 consecutive years. Embecta is clearly the better dividend stock, given its higher yield and lower payout ratio.
Atrion has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Atrion has a net margin of 10.60% compared to Atrion's net margin of 6.20%. Embecta's return on equity of 7.76% beat Atrion's return on equity.
Summary
Atrion beats Embecta on 10 of the 19 factors compared between the two stocks.
Get Embecta News Delivered to You Automatically
Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
